



(Please scan this QR Code to view the Prospectus)



SAHAJANAND MEDICAL TECHNOLOGIES LIMITED

(TO BE LISTED ON THE MAIN BOARD OF BSE AND NSE)

Our Company was initially formed as a partnership firm named 'M/s Sahajanand Vascular Technoventions' pursuant to a partnership deed dated October 25, 1999. Subsequently, pursuant to a partnership deed dated September 30, 2001, the partnership firm was re-constituted, and the name of the partnership firm was changed to 'M/s Sahajanand Medical Technologies'. Subsequently, the partnership firm was converted into a joint stock company and was registered as a private limited company named 'Sahajanand Medical Technologies Private Limited' pursuant to a certificate of incorporation dated October 18, 2001, issued by the Registrar of Companies, Gujarat, Dadra & Nagar Haveli, in accordance with provisions of the Companies Act, 1956. Subsequently, our Company was converted into a public limited company, pursuant to a special resolution of our Shareholders dated April 27, 2021, and the name of our Company was changed to 'Sahajanand Medical Technologies Limited', and a fresh certificate of incorporation dated May 7, 2021 was issued to our Company by the Registrar of Companies, Gujarat at Ahmedabad ("RoC"). For details of changes in the name and registered office address of our Company, see "**History and Certain Corporate Matters**" on page 298 of the Prospectus dated October 19, 2026 ("**Prospectus**").

Registered Office: Sahajanand Estate, Wakharia Wadi, NR. Dabholi Char Rasta, Nani Ved, Ved Road, Surat, Gujarat – 395 004, India; **Corporate Office:** Unit No. 402 & 412, A Wing, 4th Floor, Kanakia Wall Street, Andheri Kurla Road, Chakala, Andheri East, Mumbai, Maharashtra- 400 093, India.
Contact Person: Deepshikha Singhal, Company Secretary and Compliance Officer; **Tel.:** 022 49564000; **E-mail:** investors.grievance@smt.in; **Website:** www.smtpl.com; **Corporate Identity Number:** U33119GJ2001PLC040121

THE PROMOTERS OF OUR COMPANY: BHARGAV DHIRAJLAL KOTADIA, DHIRAJLAL VALLABHBHAI KOTADIA, PRIYANKA DHIRAJLAL COHEN AND SHREE HARI TRUST

Our Company has filed the Prospectus dated October 19, 2026 with the RoC, and the Equity Shares are proposed to be listed on the BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE") and trading is expected to commence on October 23, 2026.

BASIS OF ALLOTMENT

INITIAL PUBLIC OFFERING OF 13,822,116 EQUITY SHARES OF FACE VALUE OF ₹1 EACH ("EQUITY SHARES") OF SAHAJANAND MEDICAL TECHNOLOGIES LIMITED (OUR "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹344 PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹ 343 PER EQUITY SHARE) (THE "OFFER PRICE") AGGREGATING TO ₹ 4,754.81 MILLION THROUGH AN OFFER FOR SALE (THE "OFFER"), CONSISTING OF 2,700,000 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING TO ₹928.80 MILLION BY SHREE HARI TRUST, 2,000,000 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING TO ₹688.00 MILLION BY DHIRAJKUMAR SAVJIBHAI VASOYA, 6,479,063 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING TO ₹2,228.80 MILLION BY SAMARA CAPITAL MARKETS HOLDING LIMITED, 1,307,875 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING TO ₹449.91 MILLION BY KOTAK PRE-IPO OPPORTUNITIES FUND, AND 1,335,178 EQUITY SHARES OF FACE VALUE OF ₹1 EACH AGGREGATING TO ₹459.30 MILLION BY NHPEA SPARKLE HOLDING B.V. (COLLECTIVELY, THE "SELLING SHAREHOLDERS" AND SUCH EQUITY SHARES, THE "OFFERED SHARES").

THE OFFER INCLUDED A RESERVATION OF UP TO 250,000 EQUITY SHARES OF FACE VALUE OF ₹1 EACH (CONSTITUTING 0.25% % OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY) AGGREGATING UP TO ₹ 86.00 MILLION FOR SUBSCRIPTION BY ELIGIBLE EMPLOYEES (THE "EMPLOYEE RESERVATION PORTION"). PURSUANT TO FINALIZATION OF BASIS OF ALLOTMENT 24,682 EQUITY SHARES WERE ALLOTTED TO EMPLOYEES UNDER THE EMPLOYEE RESERVATION PORTION. THE OFFER LESS THE EMPLOYEE RESERVATION PORTION IS HEREINAFTER REFERRED TO AS THE "NET OFFER". THE OFFER AND THE NET OFFER CONSTITUTED 13.60% %AND 13.57% % OF OUR POST-OFFER PAID-UP EQUITY SHARE CAPITAL, RESPECTIVELY.

ANCHOR INVESTOR OFFER PRICE : ₹344 PER EQUITY SHARE OF FACE VALUE OF ₹1 EACH
OFFER PRICE: ₹344 PER EQUITY SHARE OF FACE VALUE OF ₹1 EACH
THE OFFER PRICE IS 344 TIMES THE FACE VALUE

Risk to Investors

For details, refer to section titled "**Risk Factors**" on page 20 of the Prospectus.

- Regulatory Compliance and Approvals Risk:** We are subject to extensive regulatory requirements in applicable jurisdictions. Any adverse action by any regulatory authority against us would negatively impact our ability to offer our products to our clients and adversely impact our business and prospects
- Manufacturing facilities risk:** We currently operate three manufacturing facilities, located in Surat Special Economic Zone ("SEZ") in Gujarat (India), Hyderabad, Telangana (India) and Nonthaburi (Thailand). Our manufacturing facilities are subject to certain risks, including quality control issues, disruptions in infrastructure facilities, and obsolete plant and machinery, which could increase our manufacturing costs or interrupt our operations and adversely impact our reputation, sales and strategies.
- Dependence on key raw material suppliers and supply chain risk:** We are dependent on the continued supply of raw materials and components, the supply and cost of which can be subject to significant variation due to factors outside our control. Additionally, we are dependent on our suppliers (our top 10 suppliers contributed to 63.61%, 59.15%, 64.37% and 58.88% of total purchases in the three months ended June 30, 2026 and in Fiscal 2026, Fiscal 2025 and Fiscal 2024, respectively) for certain raw materials and components and a single supplier for certain components and an inability to procure the required quality and quantity, at competitive prices, our business, financial condition, cash flows and results of operations may be adversely affected.
- Dependence on Vascular Intervention Products, Including Supraflex Cruz:** A majority of our revenues are from the sale of Vascular Intervention devices (contributed to 60.40%, 61.14%, 65.86% and 68.57% of our revenue from operations in the three months ended June 30, 2026 and in Fiscals 2026, 2025 and 2024, respectively). Additionally, the sale of the Supraflex Cruz, which forms part of our VI devices portfolio contributed to 39.00%, 37.17%, 42.06% and 47.84% of our revenue from operations in the three months ended June 30, 2026, and in Fiscals 2026, 2025 and 2024, respectively. Any adverse impact on sales of products within this vertical, or of the Supraflex Cruz would adversely affect our business, results of operations and profitability.
- Pricing Regulation Risk:** Regulatory uncertainty associated with pricing of medical devices could adversely affect the marketing, pricing and demand for our products, which may affect our financial condition and results of operations
- Forex risk:** A significant portion of our revenues and expenses is denominated in foreign currencies across the countries where we sell products, procure raw materials, and operate subsidiaries, while our financial reporting is in Indian Rupees, exposing us to foreign exchange fluctuations that may impact our results of operations. Set out below are details of our revenue from customers outside India, which are denominated in foreign currency and our Company's imports in foreign currencies.

Particulars	Three months June 30, 2026	Fiscal		
		2026	2025	2024
Revenues from location of customers outside India (₹ million)	2,678.23	8,942.01	7,042.28	5,878.44
Revenues from location of customers outside India as a % of total revenue from operations (%)	76.16%	73.87%	68.71%	65.20%
Imports in foreign currencies (₹ million)	907.47	2,410.02	1,954.09	2,075.98

- Distribution Network Dependence:** Our ability to expand and grow our product reach depends significantly on the effective management and performance of our distribution network, and any inability to identify, appoint or manage distributors, any loss of key distributors, disruptions in distribution activities, or non-compliance by distributors including in jurisdictions where product approvals are held in their name may limit our ability to market and sell our products and may adversely affect our business, financial condition, cash flows and results of operations. Set out below are details of the contribution towards revenue by our top distributor, top five distributors and top 10 distributors for the years/period indicated:

Particulars	Three months ended June 30, 2026		Fiscal					
			2026		2025		2024	
	Amount (₹ million)	% of revenue from operations	Amount (₹ million)	% of revenue from operations	Amount (₹ million)	% of revenue from operations	Amount (₹ million)	% of revenue from operations
Top distributor	95.37	2.71%	364.19	3.01%	399.98	3.90%	558.16	6.19%
Top five distributors	401.15	11.41%	1,182.44	9.77%	1,410.95	13.77%	1,724.28	19.12%
Top 10 distributors	654.21	18.60%	1,901.20	15.71%	2,153.36	21.01%	2,374.66	26.34%

- Technology related risk:** We face intense competition and may be unable to adapt to the rapid technological changes in the medical devices industry, which could adversely affect our business, results of operations and financial conditions
- Intellectual Property Protection Risks:** We depend on our ability to protect and enforce our intellectual property portfolio, which currently comprises 119 granted patents globally with 80 applications pending, 272 registered trademarks, 16 registered copyrights, five registered designs and various applications under process as on the date of the Prospectus, and any inability to obtain, maintain or defend these rights, any objections or delays in pending registrations, limitations on enforcement in certain jurisdictions, expiry of existing protections, or claims that our products infringe third-party rights may adversely affect our competitive position, delay product launches, restrict commercialization and negatively impact our business, financial condition and results of operations.
- R&D Risk:** Our future growth is dependent upon our R&D capabilities and development of new products and enhancement of existing products, and a failure to effectively develop and commercialize new products would materially and adversely affect our business, financial condition, results of operations and prospects. Further, our operating margins are subject to fluctuation on account of high allocation to R&D. As of June 30, 2026, we have 156 professionals (including four consultants) and employees working in the R&D department. Set out below are details of our Research and Development Expenses for the years/period indicated.

Particulars	Three months ended June 30, 2026		Fiscal					
	Amount (₹ million)	% of revenue from operations	Amount (₹ million)	% of revenue from operations	Amount (₹ million)	% of revenue from operations	Amount (₹ million)	% of revenue from operations
R&D Expenses	347.43	9.88%	1,041.64	8.61%	929.86	9.07%	814.63	9.04%

- Past Financial Losses:** Our Company and certain of our Subsidiaries, have incurred losses in the past, details of which are set out below for the years/period indicated:

Particulars	Three months ended June 30, 2026		Fiscal			
			2026	2025	2024	
			(in ₹ million)			
Sahajanand Medical Technologies Limited (on a consolidated basis)	-	-	-	-	-	(73.54)
Sahajanand Medical Technologies Limited (on a standalone basis)	-	-	-	-	-	(79.18) (344.59)
SMT Cardiovascular Private Limited* (on a standalone basis)	(28.00)	-	(81.14)	-	-	(130.31)
SMT Switzerland AG* (on a standalone basis)	(4.28)	(56.31)	(46.67)	-	-	(40.05)
SMT USA Ltd* (on a standalone basis)	-	-	(0.12)	-	-	(1.16)
Vascular Innovations Co Ltd*	(106.64)	(120.07)	-	-	-	-
SMT CIS LLC* (on a standalone basis)	(2.13)	-	-	-	-	-

*As per the Restated Consolidated Financial Information; for details see "Restated Consolidated Financial Information - Note 39" on page 407of the Prospectus

- Geographical risk:** We sold our products across 65 countries (including India) in the three months ended June 30, 2026 and 77 countries (including India), in Fiscal 2026. Set out below are details of the revenue generated from various geographies for the years/period indicated.

Geographies	Three months ended June 30, 2026		Fiscal					
	Revenue (₹ million)	% of revenue from operations	Revenue (₹ million)	% of revenue from operations	Revenue (₹ million)	% of revenue from operations	Revenue (₹ million)	% of revenue from operations
India	838.46	23.84%	3,163.03	26.13%	3,206.51	31.28%	3,137.60	34.80%
Europe	1,325.35	37.69%	4,680.04	38.66%	3,377.55	32.96%	2,661.21	29.52%
Rest of world (RoW)	1,352.88	38.47%	4,261.97	35.21%	3,664.73	35.76%	3,217.23	35.68%
Total revenue from operations	3,516.69	100.00%	12,105.04	100.00%	10,248.79	100.00%	9,016.04	100.00%

We are subject to a number of market, business, financial, legal and regulatory risks and uncertainties with respect to our international operations that could have a material impact on our business, financial condition or results of operations.

- Working capital risk:** Our business requires significant amount of working capital, including to finance the purchase of raw materials and components, maintenance of adequate levels of inventory and execution of manufacturing processes. Set out below are details of our working capital requirements for the years/period indicated.

Particulars	Three months ended June 30, 2026	Fiscal		
		2026	2025	2024
Average Working Capital ¹ (in ₹ million)	3,364.71	2,914.40	2,542.48	2,639.06
Working Capital Turnover Ratio ²	1.05	4.15	4.03	3.42

Notes:

- Average Working Capital is defined as Opening Net Working capital plus closing Net Working capital divided by two.*
- Working Capital Turnover Ratio is calculated by dividing Revenue from operations by Average Working Capital. Net Working Capital is defined as Total Current Assets minus Total Current Liabilities.*
Also see "Management's Discussion and Analysis of Financial Condition and Results of Operations – Non-GAAP Measures" on page 434 of the Prospectus.
- Approvals Risk:** We are required to obtain, renew or maintain statutory and regulatory permits, licenses and approvals in relation to our manufacturing facilities, and any delay or inability in obtaining, renewing or maintaining such permits, licenses and approvals could result in an adverse effect on our business, financial condition, cash flows and results of operations. Further, our manufacturing facilities are subject to periodic inspections and audits by various regulatory authorities and clients.
- Our growth strategy includes strengthening our existing businesses as well as expanding our market presence in new geographies. We cannot assure you that our growth strategies will be successful or that we will be able to continue to expand into new geographies.
- Competition:** The medical device market is intensely competitive and is characterized by extensive R&D and rapid technological change. Our competitors include multinational companies as well as domestic companies. Customers consider various factors such as product quality, technology, breadth of product portfolio, cost, delivery and service, as well as quality and depth of relationships before choosing a medical device brand. We face intense competition and may be unable to adapt to the rapid technological changes in the medical devices industry, which could adversely affect our business, results of operations and financial conditions.
- Offer related risk:** The Offer includes an offer for sale of up to 13,822,116 Equity Shares aggregating up to ₹ 4,754.81 million by the Selling Shareholders. The entire proceeds from the Offer for Sale (after deducting applicable Offer expenses) will be paid to the Selling Shareholders, in proportion of the respective portion of their Offered Shares, and our Company will not receive any such proceeds from the Offer for Sale
- Weighted average cost of acquisition of Equity Shares transacted in the last one year, eighteen months and three years preceding the date of the Prospectus

Period	Weighted Average Cost of Acquisition (in ₹)*	Cap Price is 'X' times the Weighted Average Cost of Acquisition	Range of acquisition price: Lowest Price - Highest Price [†] (in ₹)
Last one year preceding the date of the Prospectus	323.17	1.06	1.00 - 395.00
Last 18 months preceding the date of the Prospectus	322.56	1.07	1.00 - 395.00
Last three years preceding the date of the Prospectus	330.80	1.04	1.00 - 395.00

*As certified by NBT and Co., Chartered Accountants, by way of certificate dated October 19, 2026.

[†]Excluding gift and bonus transactions

- The average cost of acquisition of Equity Shares by our Promoters and the Selling Shareholders as on the date of the Prospectus is given below and offer price at upper end of the price band is ₹ 344 :

Name	Number of Equity Shares of face value of ₹ 1 each held	Average cost of acquisition per Equity Share (in ₹)*
Promoters		
Bhargav Dhirajlal Kotadia	5,000	6.00
Shree Hari Trust [†]	37,309,589	13.45
Dhirajlal Vallabhbhai Kotadia	Nil	NA
Priyanka Dhirajlal Cohen	Nil	NA
Selling Shareholders		
Dhirajkumar Savjibhai Vasoya [®]	4,082,700	0.63
Samara Capital Markets Holding Limited	27,479,063	46.77
Kotak Pre IPO Opportunities Fund	4,767,672	269.22
NHPEA Sparkle Holding B.V.	14,328,266	97.58

*Calculated as per FIFO method | [†] Also a selling shareholder | [®] Also a member of Promoter Group

- The details of Price/Earnings ratio, Earnings per share, Return on net worth, and NAV, for our Company and peer group are as follows:

Name of the Company	Total Revenue from operations (₹ in million)	Face Value (₹ per share)	P/E ratio as on October 06, 2026 ²⁾	Closing price as on October 06, 2026	EPS for the Financial Year 2026 (₹)		Return on Net Worth (%)	Net Asset Value per equity share (₹)
					Basic	Diluted		
Sahajan and Medical Technologies Limited ⁴	12,105.04	1	NA	NA	6.67	6.48	10.60%	62.76
Listed peers*								
Poly Medicure Limited	18,752.59	5	51.40	1,632.25	31.79	31.75	10.37%	306.40
Laxmi Dental Limited	2,778.58	2	36.35	191.10	5.27	5.26	11.91%	44.27

⁶Sourced from the Restated Consolidated Financial Information for the year ended March 31, 2026.

* Note for Listed Peers:

- Revenue from Operations means Revenue from sale of products and other operating revenue. All the financial information for listed industry peer mentioned above is sourced from the FY26 annual report for the year ended March 31, 2026*
- P/E Ratio has been computed based on the closing market price of equity shares on BSE on October 06, 2026 divided by the Diluted EPS provided.*
- Return on Net Worth (%) = Net Profit after tax attributable to owners of the parent for the year ended March 31, 2026 / Net worth at the end of the year*
- Net worth has been calculated as the sum of equity share capital and other equity, excluding capital reserve, amalgamation reserve and non-controlling interest.*
Net Asset Value per Equity Share = Net worth attributable to owners of the company divided by Closing Number of Equity Shares multiplied by one million
- Weighted Average Return on Net Worth for Fiscals 2026, 2025 and 2024 is 6.14% and the return on networth for three month period ended June 30, 2026 is 2.31% (not annualized)
- The four BRLMs associated with the Offer have handled 79 public issues in the past three years, out of which 25 issues closed below the offer price on listing date

Name of BRLMs	Total public issues	Issues Closed Below issue Price on listing date
Motilal Oswal Investment Advisors Limited	28	8
Avendus Capital Private Limited	6	2
HSBC Securities and Capital Markets (India) Private Limited	11	4
Nuvama Wealth Management Limited	19	9
Common issues handled by the BRLMs	15	2
Total	79	25

...continued from previous page.

BID/OFFER PROGRAMME

ANCHOR INVESTOR BIDDING DATE: WEDNESDAY, OCTOBER 14, 2026

BID/ OFFER OPENED ON: THURSDAY, OCTOBER 15, 2026 | BID/ OFFER CLOSED ON: MONDAY, OCTOBER 19, 2026

This Offer was made in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended, read with Regulation 31 of the SEBI ICDR Regulations. The Offer was made through the Book Building Process and in compliance with Regulation 6(1) of the SEBI ICDR Regulations wherein in terms of Regulation 32(1) of the SEBI ICDR Regulations, not more than 50% of the Net Offer was made available for allocation on a proportionate basis to Qualified Institutional Buyers (“QIBs”, and such portion, the “**QIB Portion**”) provided that our Company, in consultation with the BRLMs, allocated up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations (“**Anchor Investor Portion**”), 40% of the Anchor Investor Portion was reserved as: (i) 33.33% for domestic Mutual Funds and (ii) 6.67% for Life Insurance Companies and Pension Funds, subject to valid Bids received from domestic Mutual Funds, Life Insurance Companies and Pension Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription or non-allocation in the Anchor Investor Portion, the balance Equity Shares were added to the Net QIB Portion. Further, 5% of the Net QIB Portion was available for allocation on a proportionate basis only to Mutual Funds and the remainder of the Net QIB Portion was available for allocation on a proportionate basis to all QIB Bidders (other than Anchor Investors) including Mutual Funds, subject to valid Bids being received at or above the Offer Price. However, if the aggregate demand from Mutual Funds was less than 5% of the QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion was added to the remaining QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Net Offer was available for allocation to Non-Institutional Bidders out of which (a) one-third of such portion was reserved for applicants with application size of more than ₹ 20.20 million and up to ₹ 1.00 million; and (b) two-third of such portion was reserved for applicants with application size of more than ₹ 1.00 million, provided that the unsubscribed portion in either of such sub-categories was allocated to applicants in the other sub-category of Non-Institutional Bidders and not less than 35% of the Net Offer was available for allocation to Retail Individual Bidders (“RIBs”) in accordance with the SEBI ICDR Regulations (“**Retail Portion**”), subject to valid Bids received from them at or above the Offer Price. Further, Equity Shares was allocated on a proportionate basis to Eligible Employees applying under the Employee Reservation Portion, subject to valid Bids received from them at or above the Offer Price. Further, all potential Bidders (except Anchor Investors) were required to mandatorily utilise the Application Supported by Blocked Amount (“**ASBA**”) process by providing details of their respective bank accounts (including UPI ID for UPI Bidders) (as defined hereinafter) in which the Bid amount was blocked by the SCSBs or the Sponsor Banks, as applicable, to participate in the Offer. Anchor Investors were not permitted to participate in the Anchor Investor Portion of the Offer through the ASBA process. For details, see “**Offer Procedure**” beginning on page 499 of the Prospectus.

The bidding for Anchor Investor opened and closed on Wednesday, October 14, 2026. The Company received 10 applications from 8 Anchor Investors for 40,71,670 Equity Shares. The Anchor Investor Offer Price was finalized at ₹344 per Equity Share. A total of 40,71,634 Equity Shares were allocated under the Anchor Investor Portion aggregating to ₹ 1,40,06,42,096.00/-.

The Offer received 3,26,807 applications for 14,28,82,550 Equity Shares resulting in 10.34 times subscription as disclosed in the Prospectus. The details of the applications received in the Offer from Retail Individual Bidders, Non-Institutional Bidders and QIBs are as under (before technical rejections):

Sl. No.	Category	No. of Applications applied*	No. of Equity Shares	Shares Reserved as per Prospectus	No. of times Subscribed	Amount (₹)
A	Retail Individual Bidders	3,06,439	1,47,27,371	47,50,241	3.10	5,06,59,81,317.00
B	Non-Institutional Bidders – More than ₹ 2 lakhs and upto ₹10 lakhs	12,421	76,51,377	6,78,606	11.28	2,63,22,44,699.00
C	Non-Institutional Bidders – More than ₹10 lakhs	7,416	2,22,56,413	13,57,212	16.40	7,65,61,75,714.00
D	Employee	480	47,343	2,50,000	0.19	1,62,66,943.00
E	Qualified Institutional Bidders (excluding Anchors Investors)	41	9,41,28,376	27,14,423	34.68	32,38,01,61,344.00
F	Anchor Investors	10	40,71,670	40,71,634	1.0	1,40,06,54,480.00
	Total	3,26,807	14,28,82,550	1,38,22,116	10.34	49,15,14,84,497.00

This includes 6,244 applications for 3,05,386 Equity Shares from Retail Individual Investors Category and 10 applications for 6,837 Equity Shares from Non-Institutional Investors (from ₹ 200,000/- to ₹ 1,000,000/-) category which were not in book but excludes bids (UPI Mandates) not accepted by investors.

Final Demand

A summary of the final demand as per NSE and BSE as on the Bid/Issue Closing Date at different Bid prices is as under:

Sr. No	Bid Price	No. of Equity Shares	% to Total	Cumulative Total	Cumulative % of Total
1	327	51,385	0.04	51,385	0.04
2	328	7,095	0.00	58,480	0.04
3	329	1,075	0.00	59,555	0.04
4	330	11,137	0.01	70,692	0.05
5	331	387	0.00	71,079	0.05
6	332	258	0.00	71,337	0.05
7	333	2,666	0.00	74,003	0.05
8	334	3,784	0.00	77,787	0.05
9	335	9,460	0.01	87,247	0.06
10	336	1,032	0.00	88,279	0.06
11	337	860	0.00	89,139	0.06
12	338	1,204	0.00	90,343	0.06
13	339	731	0.00	91,074	0.06
14	340	8,901	0.01	99,975	0.07
15	341	1,935	0.00	1,01,910	0.07
16	342	7,783	0.01	1,09,693	0.08
17	343	9,761	0.01	1,19,454	0.08
18	344	12,79,86,791	87.73	12,81,06,245	87.82
19	CUT-OFF	1,77,74,910	12.18	14,58,81,155	100.00
	TOTAL	14,58,81,155	100.00		

*The Basis of Allotment was finalized in consultation with the Designated Stock Exchange, being NSE on October 21, 2026.

A. Allotment to Retail Individual Bidders (After Technical Rejections) (including ASBA Applications)

The Basis of Allotment to the Retail Individual Bidders, who have bid at cut-off or at the Issue Price of ₹344 per Equity, was finalized in consultation with NSE. This category has been subscribed to the extent of 2.92 times. The total number of Equity Shares Allotted in Retail Individual Bidders category is 48,29,103 Equity Shares to 1,12,304 successful applicants. The category-wise details of the Basis of Allotment are as under:

Sr. No	Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares Allotted per Bidder	Ratio	Total No. of Equity Shares allotted*
1	43	2,82,760	96.22	1,21,58,680	86.14	43	167:437	46,46,451
2	86	5,894	2.01	5,06,884	3.59	43	81:212	96,879
3	129	1,734	0.59	2,23,686	1.58	43	81:212	28,509
4	172	746	0.25	1,28,312	0.91	43	81:212	12,255
5	215	638	0.22	1,37,170	0.97	43	81:212	10,492
6	258	213	0.07	54,954	0.39	43	81:213	3,483
7	301	333	0.11	1,00,233	0.71	43	127:333	5,461
8	344	90	0.03	30,960	0.22	43	34:90	1,462
9	387	73	0.02	28,251	0.20	43	28:73	1,204
10	430	207	0.07	89,010	0.63	43	79:207	3,397
11	473	58	0.02	27,434	0.19	43	22:58	946
12	516	53	0.02	27,348	0.19	43	20:53	860
13	559	1,076	0.37	6,01,484	4.26	43	81:212	17,673
14	0	4247 Allottees from Serial no 2 to 13 Additional 1(one) share				1	31:4247	31
	TOTAL	2,93,875	100.00	1,41,14,406	100.00			48,29,103

*This includes spillover of 78,862 Equity Shares from Employee category

B. Allotment to Non-Institutional Bidders (more than ₹2 Lakh and upto ₹10 Lakh) (After Technical Rejections) (including ASBA Applications)

The Basis of Allotment to the Non-Institutional Bidders (more than ₹2 Lakh and upto ₹10 Lakh), who have bid at the Issue Price of ₹344 per Equity Share or above, was finalized in consultation with NSE. This category has been subscribed to the extent of 10.94 times. The total number of Equity Shares allotted in this category is 6,89,872 Equity Shares to 1,145 successful applicants. The category-wise details of the Basis of Allotment are as under:

Sr. No	Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares allotted per Bidder	Ratio	Total No. of Equity Shares allotted*
1	602	11797	96.21	71,01,794	94.06	602	59:631	6,64,006
2	645	224	1.83	1,44,480	1.91	602	21:224	12,642
3	688	28	0.23	19,264	0.26	602	3:28	1,806
4	731	17	0.14	12,427	0.16	602	2:17	1,204
5	774	15	0.12	11,610	0.15	602	1:15	602
6	817	6	0.05	4,902	0.06	602	1:6	602
7	860	27	0.22	23,220	0.31	602	3:27	1,806
8	903	11	0.09	9,933	0.13	602	1:11	602
9	946	1	0.01	946	0.01	602	0:1	0
10	989	2	0.02	1,978	0.03	602	0:2	0
13	1,161	4	0.03	4,644	0.06	602	0:4	0
14	1,204	12	0.10	14,448	0.19	602	1:12	602
15	1,247	1	0.01	1,247	0.02	602	0:1	0
16	1,290	8	0.07	10,320	0.14	602	1:8	602
17	1,333	2	0.02	2,666	0.04	602	0:2	0
18	1,376	1	0.01	1,376	0.02	602	0:1	0
19	1,419	44	0.36	62,436	0.83	602	4:44	2,408
20	1,462	9	0.07	13,158	0.17	602	1:9	602
21	1,505	7	0.06	10,535	0.14	602	1:7	602
22	1,548	1	0.01	1,548	0.02	602	0:1	0
23	1,591	2	0.02	3,182	0.04	602	0:2	0
24	1,720	3	0.02	5,160	0.07	602	0:3	0
25	1,763	1	0.01	1,763	0.02	602	0:1	0
26	1,806	6	0.05	10,836	0.14	602	1:6	602
27	1,892	1	0.01	1,892	0.03	602	0:1	0
34	2,795	3	0.02	8,385	0.11	602	0:3	0

35	2,838	1	0.01	2,838	0.04	602	0:1	0
36	2,881	11	0.09	31,691	0.42	602	1:11	602
37	0	42 Allottees from Serial no 2 to 36 Additional 13 shares				13	1:1	546
38	0	42 Allottees from Serial no 2 to 36 Additional 1(one) share				1	36:42	36
	TOTAL	12262	100.00	75,50,542	100.00			6,89,872

*This includes a spillover of 11,266 Equity Shares from Employee category.

C. Allotment to Non-Institutional Bidders (more than ₹10Lakh) (After Technical Rejections) (including ASBA Applications)

The Basis of Allotment to the Non-Institutional Bidders (more than ₹10 Lakh), who have bid at the Issue Price of ₹344 per Equity Share or above, was finalized in consultation with NSE. This category has been subscribed to the extent of 16.08 times. The total number of Equity Shares allotted in this category is 13,79,744 Equity Shares to 2,291 successful applicants. The category-wise details of the Basis of Allotment are as under: (Sample)

Sr. No	Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares allotted per applicant	Ratio	Total No. of Equity Shares allotted*
1	2,924	7164	96.93	2,09,47,536	94.43	602	58:187	13,37,644
2	2,967	86	1.16	2,55,162	1.15	602	27:86	16,254
3	3,010	50	0.68	1,50,500	0.68	602	16:50	9,632
4	3,053	9	0.12	27,477	0.12	602	3:9	1,806
5	3,096	10	0.14	30,960	0.14	602	3:10	1,806
6	3,139	3	0.04	9,417	0.04	602	1:3	602
7	3,225	2	0.03	6,450	0.03	602	1:2	602
8	3,397	6	0.08	20,382	0.09	602	2:6	1,204
9	3,440	3	0.04	10,320	0.05	602	1:3	602
10	3,526	10	0.14	35,260	0.16	602	3:10	1,806
11	3,784	4	0.05	15,136	0.07	602	1:4	602
12	4,171	7	0.09	29,197	0.13	602	2:7	1,204
13	4,300	5	0.07	21,500	0.10	602	2:5	1,204
14	4,386	3	0.04	13,158	0.06	602	1:3	602
15	5,805	2	0.03	11,610	0.05	602	1:2	602
16	8,600	3	0.04	25,800	0.12	602	1:3	602
17	3,483	1	0.01	3,483	0.02	602	0:1	0
18	3,870	1	0.01	3,870	0.02	602	0:1	0
36	45,150	1	0.01	45,150	0.20	602	0:1	0
37	55,900	1	0.01	55,900	0.25	602	0:1	0
38	58,265	1	0.01	58,265	0.26	602	0:1	0
39	1,10,424	1	0.01	1,10,424	0.50	602	0:1	0
40	1,16,100	1	0.01	1,16,100	0.52	602	0:1	0
41	0	All applicants from Serial no 17 to 40 for 1 (one) lot of 602 shares				602	4:24	2,408
42	0	2291 Allottees from Serial no 1 to 41 Additional 1(one) share				1	13:53	562
	TOTAL	7391	100.00	2,21,82,711	100.00			13,79,744

*This includes a spillover of 22,532 Equity Shares from Employee category.

D. Allotment to Eligible Employees (After Rejections) (including ASBA Applications)

The Basis of Allotment to the Employee Reservation Portion, who have bid at the Offer Price of ₹344 per Equity Share or above, was finalized in consultation with NSE. This category has been subscribed to the extent of 0.10 times. The total number of Equity Shares allotted in this category is 24,682 Equity Shares to 147 successful applicants. The category-wise details of the Basis of Allotment are as under:

Sr. No	Category	No. of Applications Received	% of Total	Total No. of Equity Shares applied	% to Total	No. of Equity Shares allotted per Bidder	Ratio	Total No. of Equity Shares allotted*
1	43	78	53.06	3,354	13.59	43	1:1	3,354
2	86	27	18.37	2,322	9.41	86	1:1	2,322
3	129	7	4.76	903	3.66	129	1:1	903
4	172	5	3.40	860	3.48	172	1:1	860
5	215	3	2.04	645	2.61	215	1:1	645
6	258	3	2.04	774	3.14	258	1:1	774
7	301	6	4.08	1,806	7.32	301	1:1	1,806
8	344	1	0.68	344	1.39	344	1:1	344
9	430	1	0.68	430	1.74	430	1:1	430
10	559	4	2.72	2,236	9.06	559	1:1	2,236
11	602	4	2.72	2,408	9.76	602	1:1	2,408
12	645	1	0.68	645	2.61	645	1:1	645
13	688	1	0.68	688	2.79	688	1:1	688
14	731	1	0.68	731	2.96	731	1:1	731
15	860	1	0.68	860	3.48	860	1:1	860
16	1419	4	2.72	5,676	23.00	1419	1:1	5,676
	TOTAL	147	100.00	24,682	100.00			24,682

*The deficit of 2,25,318 equity shares in the employee category has been spilled over in other categories 5,633 shares in Mutual Fund Reservation; 1,07,02